FULL VET CRO

OCR, partenaire de vos études cliniques
de médecine comparative

OCR est spécialisé dans la conception et la mise en oeuvre d’études cliniques intégrant des animaux de compagnie naturellement malades
pour l’évaluation de solutions thérapeutiques en santé humaine.

RENCONTREZ OCR

COMMUNIQUÉS DE PRESSE

  • LILLE, 6TH SEPTEMBER 2016

    OCR the company revolutionising the selection of effective drug candidates for cancer, raises €1.25m from Newfund, NFA and the management team in order to accelerate its growth.

  • LILLE, 16TH JULY 2015

    OCR and Pierre Fabre’s Phase I Clinical Pharmacology Study published in prestigious Clinical Cancer Research journal.

  • LILLE, O2ND APRIL 2015

    OCR and Ecrins Therapeutics initiate €1.9m “Dog to Man” pioneering translational research programme to advance human and vet oncology treatment.

  • LILLE, 23RD MARCH 2015

    OCR and PRISM announce ground-breaking research collaboration to advance real-time diagnosis using mass spectrometry.

  • LILLE, 30TH JANUARY 2015

    OCR strengthens veterinary and R&D expertise to respond to the needs of the pharmaceutical industry.

Ne manquez plus aucune information sur OCR,
abonnez-vous à notre Newsletter !